Molnupiravir: a Covid cure for the UK?

Britain has become the first country to approve a Covid-19 antiviral pill.  It would be a history changer for the long fight between humans and the virus.

Elderly and vulnerable citizens will enjoy preferential access to this recommended drug, known as Molnupiravir. It is also aimed at patients who are suffering from mild to moderate Covid-19 symptoms to reduce hospitalisation as well as the risk of death.

More than 480,000 doses of Molnupiravir have been purchased, so these pills can be made available by mid- November onwards.

Molnupiravir works as a potent interference when the virus attempts to replicate in the human body. The Medicines and Healthcare products Regulatory Agency (MHRA) recommends that patients take the pills in the first five days when symptoms emerge.

Last month, the US announced clinical trial results and declared that after taking Molnupiravir pills for five consecutive days, nearly half of critically sick patients would suffer lower risks of hospitalisation or death. However, the US has not released data related to drug safety yet.

June Raine, the chief of MHRA, called on the public to believe Molnupiravir’s safety profile, efficacy, and optimal use. Molnupiravir has gained professional approval from MHRA.

The Director of England National Health Service, Stephen Powis, said: “Britain heads into one of the most challenging winters ever.” He added that the government should vigorously promote Molnupiravir if it effectively reduces hospitalisation and death risks of patients with severe covid-19 symptoms.

Unquestionably, Molnupiravir is a pioneering invention in the medical field. If it functions as promised, humans may win the fight against Covid in the not too distant future.

[Tweet ”“]

Words: Catherine Chu, Subbing: Hannah Ozkadi

Accessibility | Cookies | Terms of use and privacy